Skip to main content
Javed Butler, MD, Cardiology, Jackson, MS

JavedButlerMD

Cardiology Jackson, MS

Heart Failure & Transplantation

President, Baylor Scott and White Research Institute Senior Vice President, Baylor Scott and White Health

Dr. Butler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Butler's full profile

Already have an account?

  • Office

    2500 N State St
    Jackson, MS 39216
    Phone+1 601-984-1000
    Fax+1 601-984-6439

Summary

  • Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute, and Senior Vice President and Maxwell A. and Gayle H. Clampitt Endowed Chair at the Baylor Scott and White Health in Dallas, TX. He is also the Distinguished Professor of Medicine at University of Mississippi in Jackson, MS. Prior to joining Baylor Scott and White Health, he served as the Patrick H. Lehan Chair in Cardiovascular Research, and Professor and Chairman of the Department of Medicine at the University of Mississippi, where he was also Professor of Physiology. Prior to joining the University of Mississippi, he was Charles A. Gargano Professor and Director of the Division of Cardiovascular Medicine and Co-Director of the Heart Institute at Stony Brook University, New York. He had served as the director for heart failure research at Emory University and director of the heart and heart-lung transplant programs at Vanderbilt University prior to that.
    He received his medical degree from the Aga Khan University and then completed residency training at Yale University, cardiology fellowship and advanced heart failure and transplant fellowships at Vanderbilt University, and cardiac imaging fellowship at the Massachusetts General Hospital at the Harvard Medical School. He has completed Master of Public Health degree from Harvard University and a Master in Business Administration from the Emory University.
    Dr. Butler is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure. He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.

Education & Training

  • Vanderbilt University Medical Center
    Vanderbilt University Medical CenterFellowship, Cardiovascular Disease, 1995 - 1998
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Internal Medicine, 1991 - 1994
  • Aga Khan Medical College
    Aga Khan Medical CollegeClass of 1990

Certifications & Licensure

  • GA State Medical License
    GA State Medical License 2006 - 2025
  • MS State Medical License
    MS State Medical License 2018 - 2025
  • NY State Medical License
    NY State Medical License 2014 - 2025
  • TN State Medical License
    TN State Medical License 1999 - 2007
  • CT State Medical License
    CT State Medical License 1994 - 1999
  • American Board of Internal Medicine Advanced Heart Failure and Transplant Cardiology
  • American Board of Internal Medicine Cardiovascular Disease

Awards, Honors, & Recognition

  • Atlanta Magazine: Top Doctors Castle Connolly, 2009-2014
  • Super Doctor SuperDoctors.com
  • Fellow (FACC) American College of Cardiology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Trends in Hospitalizations for Heart Failure and Ischemic Heart Disease Among US Adults with Diabetes  
    Michael C Honigberg, Ravi B Patel, Javed Butler, Darren K Mcguire, JAMA Cardiology
  • Effect of a Self-Care Intervention on 90-Day Outcomes in Patients with Acute Heart Failure Discharged from the Emergency Department  
    Phillip D Levy, Deborah J Diercks, Gregory J Fermann, Brian Hiestand, Joann Lindenfeld, Jennifer Martindale, Javed Butler, JAMA Cardiology
  • Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients with Heart Failure with Reduced Ejection Fraction in US Clinical Practice  
    Muthiah Vaduganathan, Javed Butler, Paul A Heidenreich, Michelle M Kittleson, Anjali Tiku Owens, Pamela N Peterson, Clyde W Yancy, Gregg C Fonarow, JAMA Cardiology
  • Join now to see all

Lectures

  • Heart Failure Prevention for All 
    Heart Failure Society of America, Bloomington, Minnesota - 9/27/2012
  • Guideline Directed Management of a NYHA Class III Patient: How to Titrate What to Avoid Tools for Success and Practical Pearls 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019
  • Selecting A First-Choice Therapy For Systolic HF: The Growing Body of Evidence 
    2019 ACC Scientific Session & Expo, New Orleans - 3/17/2019

Authored Content

  • Trends in HF Hospitalizations Among Young Adults in the United States from 2004 to 2018May 2022
  • Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureAugust 2020
  • Cardiovascular and Renal Outcomes with Empagliflozin in Heart FailureAugust 2020
  • Heart Failure Epidemiology in Patients with Diabetes Mellitus Without Coronary Heart DiseaseNovember 2018
  • Patient and Practice Characteristics Associated with Sacubitril/Valsartan Use in the United StatesSeptember 2018
  • Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients with Type 2 DiabetesMarch 2018
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction A Report of the American College of Cardiology Task Force on Expert Consensus Decision PathwaysJanuary 2018
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection Fraction A Report of the American College of Cardiology Task Force on Expert Consensus Decision PathwaysJanuary 2018
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure TreatmentDecember 2017
  • 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure with Reduced Ejection FractionDecember 2017
  • Join now to see all

Press Mentions

  • URMC to Lead $27M Heart Failure Medication Study
    URMC to Lead $27M Heart Failure Medication StudyAugust 13th, 2024
  • Effect of Dapagliflozin on Health Status in Patients with Preserved or Mildly Reduced Ejection Fraction
    Effect of Dapagliflozin on Health Status in Patients with Preserved or Mildly Reduced Ejection FractionDecember 14th, 2022
  • Adding Salt to Foods and Risk of Cardiovascular Disease
    Adding Salt to Foods and Risk of Cardiovascular DiseaseDecember 1st, 2022
  • Join now to see all

Professional Memberships